The healthcare sector is really an oddball when it comes to valuations. Whereas companies in most sectors are valued based on their level of sales and profit growth, a significant number of healthcare companies wind up being valued based on speculation about how many people their drug, device, or diagnostic portfolio could eventually treat.
Losing money can be fairly common in the healthcare sector, especially if a company is predominantly in the clinical stages of its drug or product development. It means healthcare companies are regularly looking to raise capital post-IPO, and that can sometimes mean dilutive stock offerings.
Hey, check out all the research scientist jobs. Post your resume today!
